Cargando…

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma

BACKGROUND: This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane. METHODS: Retrospective study of 45 patients with adrenocortical carcinoma who were treated at the Centre hos...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagnon, Nadia, Bernard, Sophie, Paquette, Martine, Alguire, Catherine, Lacroix, André, Hétu, Pierre-Olivier, Olney, Harold J, Bourdeau, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259324/
https://www.ncbi.nlm.nih.gov/pubmed/37435450
http://dx.doi.org/10.1530/EO-21-0021
_version_ 1785057636034543616
author Gagnon, Nadia
Bernard, Sophie
Paquette, Martine
Alguire, Catherine
Lacroix, André
Hétu, Pierre-Olivier
Olney, Harold J
Bourdeau, Isabelle
author_facet Gagnon, Nadia
Bernard, Sophie
Paquette, Martine
Alguire, Catherine
Lacroix, André
Hétu, Pierre-Olivier
Olney, Harold J
Bourdeau, Isabelle
author_sort Gagnon, Nadia
collection PubMed
description BACKGROUND: This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane. METHODS: Retrospective study of 45 patients with adrenocortical carcinoma who were treated at the Centre hospitalier de l’Université de Montréal. Clinical and biochemical data were collected, including lipid profiles before and during the first year of treatment with mitotane. RESULTS: Among the 45 studied patients, 26 (58%) had a complete lipid profile before the introduction of mitotane and at least 1 lipid profile during the first year of treatment, and 19 patients (42%) had a lipid profile following initiation of the treatment. Among the 26 patients who had lipid profiles before and after the introduction of mitotane, the increase of LDL-c was 2.19 mmol/L (76%) (P< 0.0001), HDL-c was 0.54 mmol/L (35%) (P= 0.0002), Tg was 1.80 mmol/L (129%) (P< 0.0001) and non-HDL-c was 2.73 mmol/L (79%) (P< 0.0001). Between the first and the sixth month of mitotane treatment, peak values (n  = 45) of LDL-c and non-HDL-c were reached in 42 patients (93%) and 37 patients (82%), respectively, whereas peak values of HDL-c were reached after 6 months of mitotane treatment in 29 patients (66%). The peak value of Tg was almost equal throughout the first year. The mean peak values of HDL-c, Tg and non-HDL-c showed significant associations with their respective mitotane concentrations (β = 0.352, P= 0.03; β = 0.406, P= 0.02 and β = 0.339, P= 0.05). CONCLUSION: The introduction of mitotane produces a clinically significant elevation of lipid parameters (LDL-c, HDL-c, Tg and non-HDL-c) during the first year of treatment.
format Online
Article
Text
id pubmed-10259324
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-102593242023-07-11 Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma Gagnon, Nadia Bernard, Sophie Paquette, Martine Alguire, Catherine Lacroix, André Hétu, Pierre-Olivier Olney, Harold J Bourdeau, Isabelle Endocr Oncol Research BACKGROUND: This study examined the magnitude of changes and the time required to observe maximal changes in LDL-c, HDL-c, triglycerides (Tg) and non-HDL-c after the introduction of mitotane. METHODS: Retrospective study of 45 patients with adrenocortical carcinoma who were treated at the Centre hospitalier de l’Université de Montréal. Clinical and biochemical data were collected, including lipid profiles before and during the first year of treatment with mitotane. RESULTS: Among the 45 studied patients, 26 (58%) had a complete lipid profile before the introduction of mitotane and at least 1 lipid profile during the first year of treatment, and 19 patients (42%) had a lipid profile following initiation of the treatment. Among the 26 patients who had lipid profiles before and after the introduction of mitotane, the increase of LDL-c was 2.19 mmol/L (76%) (P< 0.0001), HDL-c was 0.54 mmol/L (35%) (P= 0.0002), Tg was 1.80 mmol/L (129%) (P< 0.0001) and non-HDL-c was 2.73 mmol/L (79%) (P< 0.0001). Between the first and the sixth month of mitotane treatment, peak values (n  = 45) of LDL-c and non-HDL-c were reached in 42 patients (93%) and 37 patients (82%), respectively, whereas peak values of HDL-c were reached after 6 months of mitotane treatment in 29 patients (66%). The peak value of Tg was almost equal throughout the first year. The mean peak values of HDL-c, Tg and non-HDL-c showed significant associations with their respective mitotane concentrations (β = 0.352, P= 0.03; β = 0.406, P= 0.02 and β = 0.339, P= 0.05). CONCLUSION: The introduction of mitotane produces a clinically significant elevation of lipid parameters (LDL-c, HDL-c, Tg and non-HDL-c) during the first year of treatment. Bioscientifica Ltd 2022-02-07 /pmc/articles/PMC10259324/ /pubmed/37435450 http://dx.doi.org/10.1530/EO-21-0021 Text en © The authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Research
Gagnon, Nadia
Bernard, Sophie
Paquette, Martine
Alguire, Catherine
Lacroix, André
Hétu, Pierre-Olivier
Olney, Harold J
Bourdeau, Isabelle
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
title Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
title_full Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
title_fullStr Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
title_full_unstemmed Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
title_short Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
title_sort characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259324/
https://www.ncbi.nlm.nih.gov/pubmed/37435450
http://dx.doi.org/10.1530/EO-21-0021
work_keys_str_mv AT gagnonnadia characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma
AT bernardsophie characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma
AT paquettemartine characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma
AT alguirecatherine characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma
AT lacroixandre characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma
AT hetupierreolivier characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma
AT olneyharoldj characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma
AT bourdeauisabelle characterizationofhyperlipidemiasecondarytomitotaneinadrenocorticalcarcinoma